Researchers develop lysosomal 'TRAP' for clearance of viruses and variants
Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have recently developed a ...
Promising Potential of Vigil Neuroscience’s VG-3927 in Alzheimer’s Treatment with a Buy Rating and $17 Price Target
Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...
pharmaphorum1y
BenevolentAI to power small molecule drug discovery
BenevolentAI has entered a two-year agreement with the MRC Technology to investigate new small molecule and antibody drug candidates. The UK-based artificial intelligence company has teamed up ...
MyChesCo on MSN6d
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has entered into an exclusive licensing agreement with Biosion, Inc., ...
labiotech1d
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...
Nature3y
Vincerx—next-generation antibody–drug conjugates with enhanced therapeutic windows
“We are particularly focused on harnessing our versatile toolbox of innovative linkers, payloads and bioconjugation chemistries to advance the next generation of small molecule and antibody ...
Nature1mon
Isotype selection in antibody engineering
Antibodies of the IgG4—but not the IgG1 ... in the presence of erythrocytes or an erythrocyte-derived small molecule, as well as under reducing conditions. Making the IgG1 core hinge more ...